WO2016065349A8 - Short non-coding protein regulatory rnas (sprrnas) and methods of use - Google Patents

Short non-coding protein regulatory rnas (sprrnas) and methods of use Download PDF

Info

Publication number
WO2016065349A8
WO2016065349A8 PCT/US2015/057259 US2015057259W WO2016065349A8 WO 2016065349 A8 WO2016065349 A8 WO 2016065349A8 US 2015057259 W US2015057259 W US 2015057259W WO 2016065349 A8 WO2016065349 A8 WO 2016065349A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
sprrnas
use
short non
coding protein
Prior art date
Application number
PCT/US2015/057259
Other languages
French (fr)
Other versions
WO2016065349A2 (en
WO2016065349A3 (en
Inventor
Li Mao
Yupin MEI
Original Assignee
University Of Maryland, Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201462068106P priority Critical
Priority to US62/068,106 priority
Application filed by University Of Maryland, Baltimore filed Critical University Of Maryland, Baltimore
Publication of WO2016065349A2 publication Critical patent/WO2016065349A2/en
Publication of WO2016065349A3 publication Critical patent/WO2016065349A3/en
Publication of WO2016065349A8 publication Critical patent/WO2016065349A8/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/113Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment; Prognosis

Abstract

The present invention provides isolated nucleic acid molecules comprising short non-coding protein regulatory RNAs (sprRNA), variants, fragments and inhibitors thereof and compositions and methods of using the same.
PCT/US2015/057259 2014-10-24 2015-10-24 Short non-coding protein regulatory rnas (sprrnas) and methods of use WO2016065349A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201462068106P true 2014-10-24 2014-10-24
US62/068,106 2014-10-24

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/521,606 US20180273941A1 (en) 2014-10-24 2015-10-24 Short Non-Coding Protein Regulatory RNAs (sprRNAs) and Methods of Use
EP15851885.2A EP3209780A4 (en) 2014-10-24 2015-10-24 Short non-coding protein regulatory rnas (sprrnas) and methods of use

Publications (3)

Publication Number Publication Date
WO2016065349A2 WO2016065349A2 (en) 2016-04-28
WO2016065349A3 WO2016065349A3 (en) 2016-07-14
WO2016065349A8 true WO2016065349A8 (en) 2016-11-10

Family

ID=55761760

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/057259 WO2016065349A2 (en) 2014-10-24 2015-10-24 Short non-coding protein regulatory rnas (sprrnas) and methods of use

Country Status (3)

Country Link
US (1) US20180273941A1 (en)
EP (1) EP3209780A4 (en)
WO (1) WO2016065349A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201808286A (en) 2016-05-11 2018-03-16 滬亞生物國際有限公司 Combination therapies of HDAC inhibitors and PD-L1 inhibitors
TW201740943A (en) 2016-05-11 2017-12-01 滬亞生物國際有限公司 Combination therapies of HDAC inhibitors and PD-1 inhibitors
CN108486247A (en) * 2018-02-12 2018-09-04 中山大学 Applications of the piRNA-54265 in terms of the diagnosis and treatment of colorectal cancer and prognostic evaluation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358535B1 (en) 1980-12-08 1986-05-13
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
KR20070085113A (en) 2004-05-11 2007-08-27 가부시키가이샤 알파젠 Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
US8173616B2 (en) * 2008-05-02 2012-05-08 The Brigham And Women's Hospital, Inc. RNA-induced translational silencing and cellular apoptosis
EP2326331A4 (en) 2008-08-18 2013-05-15 Merck Sharp & Dohme Novel lipid nanoparticles and novel components for delivery of nucleic acids
WO2010080724A1 (en) 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
TR201811076T4 (en) 2009-06-10 2018-08-27 Arbutus Biopharma Corp Enhanced lipid formulation.
EP3072881A1 (en) 2009-08-20 2016-09-28 Sirna Therapeutics, Inc. Novel cationic lipids with various head groups for oligonucleotide delivery
WO2011043913A2 (en) 2009-10-08 2011-04-14 Merck Sharp & Dohme Corp. Novel cationic lipids with short lipid chains for oligonucleotide delivery
EP2525781A1 (en) 2010-01-22 2012-11-28 Schering Corporation Novel cationic lipids for oligonucleotide delivery
WO2011149733A2 (en) 2010-05-24 2011-12-01 Merck Sharp & Dohme Corp. Novel amino alcohol cationic lipids for oligonucleotide delivery
DK2575767T3 (en) 2010-06-04 2017-03-13 Sirna Therapeutics Inc However unknown low molecular cationic lipids to process oigonucleotides
CA2809858C (en) 2010-09-20 2019-11-12 Merck Sharp & Dohme Corp. Novel low molecular weight cationic lipids for oligonucleotide delivery
US9029604B2 (en) 2010-09-30 2015-05-12 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
EP3485913A1 (en) 2010-10-21 2019-05-22 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
EP2635265B1 (en) 2010-11-05 2018-04-04 Sirna Therapeutics, Inc. Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
DK2655621T3 (en) 2010-12-20 2018-08-13 Massachusetts Gen Hospital Polycomb-associated non-coding RNAS
DK2663548T3 (en) 2011-01-11 2017-07-24 Alnylam Pharmaceuticals Inc Pegyled lipids and their use for pharmaceutical supply
CA2858581A1 (en) * 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
EP2794881B1 (en) 2011-12-22 2018-06-27 InteRNA Technologies B.V. Mirna for treating head and neck cancer

Also Published As

Publication number Publication date
US20180273941A1 (en) 2018-09-27
EP3209780A2 (en) 2017-08-30
EP3209780A4 (en) 2018-09-19
WO2016065349A3 (en) 2016-07-14
WO2016065349A2 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
SG10201906513WA (en) Crispr hybrid dna/rna polynucleotides and methods of use
WO2016057951A3 (en) Crispr oligonucleotides and gene editing
EP3337476A4 (en) Compounds and methods for the targeted degradation of bromodomain-containing proteins
EP3132025A4 (en) Methods and compositions for modifying genomic dna
BR112016024644A2 (en) nucleic acid vaccines
MX2016007541A (en) Modified nucleic acid molecules and uses thereof.
EP3270917A4 (en) Compounds and methods for the enhanced degradation of targeted proteins
WO2015010135A3 (en) Compositions for modulating tau expression
EP3325665A4 (en) Methods of amplifying nucleic acid sequences
PH12018501378A1 (en) Compositions and methods for the treatment of hemoglobinopathies
EP3325017A4 (en) Oligonucleotide compositions and methods thereof
EP3359523A4 (en) Oligonucleotide compositions and methods thereof
MX2015011898A (en) Pyrazolo compounds and uses thereof.
EP3041948A4 (en) Alternative nucleic acid molecules containing reduced uracil content and uses thereof
EP3188763A4 (en) Methods and compositions for rna-directed target dna modification
WO2016011306A3 (en) Terminal modifications of polynucleotides
WO2016110453A8 (en) A crispr-cas system for a filamentous fungal host cell
WO2015143046A3 (en) Methods and compositions for regulation of zinc finger protein expression
EP3095460A4 (en) Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
WO2015085318A3 (en) Targeted adaptive vaccines
WO2015119941A3 (en) Genome fractioning
WO2016066757A3 (en) Protease variants and polynucleotides encoding same
EP3307872A4 (en) Methods and compositions for efficient delivery of nucleic acids and rna-based antimicrobials
EP3322711A4 (en) Hpk1 inhibitors and methods of using same
EP3604535A3 (en) Methods and compositions for weed control

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15851885

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 15521606

Country of ref document: US

NENP Non-entry into the national phase in:

Ref country code: DE

REEP

Ref document number: 2015851885

Country of ref document: EP